Nicotinamide clinical trials
Nicotinamide is named as an intervention in 6 current clinical trials in our USA, France, Spain, Canada and Brazil registers. 5 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is EpiDestiny, Inc (1). The most-studied condition is Sickle Cell Disease.
Where Nicotinamide is approved
All regulators →- 2 EU orphan designations, most recently for treatment of sickle cell disease (19 Oct 2020, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Nicotinamide
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Nicotinamide works
All drug targets →- Alzheimer diseasePhase 3
- Acute kidney injuryPhase 3
- Bladder transitional cell carcinomaPhase 3
- Brain injuryPhase 3
- CholelithiasisPhase 3
- Diabetic autonomic neuropathyPhase 3
- Diabetic polyneuropathyPhase 3
- HyperphosphatemiaPhase 3
- Open-angle glaucomaPhase 3
- Type 2 diabetes mellitusPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1140, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Nicotinamide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Nicotinamide
- ATC code
- A11HA01
- ChEMBL
- CHEMBL1140
- DrugBank
- DB02701
- PubChem CID
- 936
- CAS number
- 98-92-0
- FDA UNII
- 25X51I8RD4
- Wikidata
- Q192423
- Wikipedia
- Nicotinamide
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Nicotinamide
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Nicotinamide across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Nicotinamide on the HPRA medicines list.
- Nicam 4% w/w GelDermal Laboratories (Ireland) Limited · PA23128/012/001 · Not marketed
Supply shortages
No entry for Nicotinamide in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Nicotinamide
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Sickle Cell Disease | 1 |
| Healthy Adults | 1 |
| Nicotinamide Adverse Reaction | 1 |
| Fatty Liver | 1 |
| Obesity | 1 |
| Hepatic Fibrosis | 1 |
| NAFLD | 1 |
| Non-melanoma Skin Cancer | 1 |
| Carcinoma, Squamous Cell | 1 |
| Carcinoma, Basal Cell | 1 |
| Keratinocyte Carcinoma | 1 |
| Hiv | 1 |
| HIV I Infection | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| EpiDestiny, Inc | 1 |
| Metro International Biotech, LLC | 1 |
| University Hospital, Angers | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Women's College Hospital | 1 |
| Federal University of São Paulo | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Brazil | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Nicotinamide trials
How many clinical trials are testing Nicotinamide?
6 current trials in our USA, France, Spain, Canada and Brazil registers name Nicotinamide as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Nicotinamide trials recruiting patients?
Yes. 5 of the 6 trials are recruiting: 2 with sites in USA, 1 with sites in Spain, 1 with sites in Canada and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Nicotinamide clinical trials?
EpiDestiny, Inc (1), Metro International Biotech, LLC (1), University Hospital, Angers (1) and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Nicotinamide licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Nicotinamide, for example Nicam 4% w/w Gel (Dermal Laboratories (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Nicotinamide shortage?
Not in the lists we track: Nicotinamide has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nicotinamide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nicotinamide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nicotinamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.